Gengraf Conversion Study in Stable Renal Allograft Transplant Recipients

Summary

The purpose of this study is to establish the therapeutic equivalence of Gengraf® with the standard treatment Neoral® for a treatment period of 6 months in stable renal allograft transplant recipients with respect to drug levels, dosage, and acute graft rejection and other adverse events.

Timeline

Start

2004-11

Primary completion

2005-12

Completion

2006-05

Drugs

Indications